Nanobiotix: Stock Soars Nearly 1000% Over a Year, Now Entering Consolidation Phase

Limited Decline Following Financial Operation and Jefferies' Upgrade

Nanobiotix's stock declines by 0.82% to €36.34 in mid-morning trading, while the SBF 120 drops by 0.93% and the CAC 40 by 0.96% during the session. The stock ranks mid-table in the broad index, not participating in the day's extreme movements. Recent sessions have been marked by a trading suspension related to a global offering of shares, followed by a rebound of nearly 11% on Friday after Jefferies raised its price target from €21.50 to €60 with a buy recommendation. The seven-day performance remains negative at nearly -15%, a direct consequence of the dilution related to the operation. Over three months, the stock maintains a gain of 65.6%, and over one year, the increase exceeds 983%, one of the strongest in the Parisian biotech sector.

Technical Setup Still Bullish Despite Recent Consolidation

Despite the decline in recent sessions, the stock remains above its three moving averages. The price is 1.25% above the MM20 at €35.89, 18.5% above the MM50 at €30.66, and nearly 78% above the MM200 at €20.40. The RSI at 53 indicates a neutral situation, following the extremes observed around the mid-May record highs. The MACD has moved back into negative territory (histogram at -0.62), reflecting the loss of momentum since the historical peak of €47.66 reached on May 18. The technical support identified at €26.34 remains distant, while the major resistance is at €46.18, in the zone of historical highs. The results of the phase 2 CONVERGE trial presented in mid-May, in partnership with Johnson & Johnson, remain the fundamental backdrop of the case. The holding of the MM20 at €35.89 will be the immediate technical reference for the continuation of the consolidation.